Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to -$23.2 million.

  • Tg Therapeutics' Cash from Operations fell 8970.09% to -$23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 14949.44%. This contributed to the annual value of -$40.5 million for FY2024, which is 2898.16% down from last year.
  • Latest data reveals that Tg Therapeutics reported Cash from Operations of -$23.2 million as of Q3 2025, which was down 8970.09% from $7.4 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Cash from Operations peaked at $83.7 million during Q3 2023, and registered a low of -$86.9 million during Q4 2021.
  • Over the past 5 years, Tg Therapeutics' median Cash from Operations value was -$28.7 million (recorded in 2025), while the average stood at -$31.0 million.
  • As far as peak fluctuations go, Tg Therapeutics' Cash from Operations skyrocketed by 34265.55% in 2023, and later tumbled by 24988.42% in 2025.
  • Quarter analysis of 5 years shows Tg Therapeutics' Cash from Operations stood at -$86.9 million in 2021, then soared by 72.53% to -$23.9 million in 2022, then soared by 44.66% to -$13.2 million in 2023, then crashed by 94.1% to -$25.6 million in 2024, then increased by 9.7% to -$23.2 million in 2025.
  • Its Cash from Operations was -$23.2 million in Q3 2025, compared to $7.4 million in Q2 2025 and -$28.7 million in Q1 2025.